NasdaqGS:INVAPharmaceuticals
Innoviva’s Earnings Swing And Buyback Might Change The Case For Investing In Innoviva (INVA)
Innoviva, Inc. has reported past second-quarter 2026 results showing revenue of US$119.59 million, up from US$100.28 million a year earlier, but shifting from a net income of US$63.69 million to a net loss of US$83.42 million, while also completing a share repurchase of 3,055,966 shares for US$66.40 million under its existing program.
Despite the quarterly loss, Innoviva’s six-month figures to June 30, 2026 show revenue rising to US$217.59 million and net income increasing to US$103.18...